330 related articles for article (PubMed ID: 15127241)
1. 153Sm-EDTMP for bone pain palliation in skeletal metastases.
Maini CL; Bergomi S; Romano L; Sciuto R
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S171-8. PubMed ID: 15127241
[TBL] [Abstract][Full Text] [Related]
2. 186Re-HEDP for metastatic bone pain in breast cancer patients.
Lam MG; de Klerk JM; van Rijk PP
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S162-70. PubMed ID: 15118846
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and toxicity of 153samarium-EDTMP in painful breast cancer bone metastases.
Dolezal J
Onkologie; 2009 Feb; 32(1-2):35-9. PubMed ID: 19209017
[TBL] [Abstract][Full Text] [Related]
4. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases.
Anderson PM; Wiseman GA; Dispenzieri A; Arndt CA; Hartmann LC; Smithson WA; Mullan BP; Bruland OS
J Clin Oncol; 2002 Jan; 20(1):189-96. PubMed ID: 11773169
[TBL] [Abstract][Full Text] [Related]
5. The Vienna protocol and perspectives in radionuclide therapy.
Sinzinger H; Palumbo B; Ozker K
Q J Nucl Med Mol Imaging; 2011 Aug; 55(4):420-30. PubMed ID: 21738115
[TBL] [Abstract][Full Text] [Related]
6. Improving the dose-myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP.
Pacilio M; Ventroni G; Basile C; Ialongo P; Becci D; Mango L
Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):238-52. PubMed ID: 24077786
[TBL] [Abstract][Full Text] [Related]
7. Clinical Efficacy and Safety Comparison of 177Lu-EDTMP with 153Sm-EDTMP on an Equidose Basis in Patients with Painful Skeletal Metastases.
Thapa P; Nikam D; Das T; Sonawane G; Agarwal JP; Basu S
J Nucl Med; 2015 Oct; 56(10):1513-9. PubMed ID: 26315829
[TBL] [Abstract][Full Text] [Related]
8. [Primary investigation of dose-effect relationship of 153Sm-EDTMP in treating multiple bone metastases].
Fan W; Chen LX; Liu XW; Tang Q; Wang GH; Zhi SF; Zeng ZY
Ai Zheng; 2006 Nov; 25(11):1395-8. PubMed ID: 17094908
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study.
Yuan J; Liu C; Liu X; Wang Y; Kuai D; Zhang G; Zaknun JJ
Clin Nucl Med; 2013 Feb; 38(2):88-92. PubMed ID: 23334120
[TBL] [Abstract][Full Text] [Related]
10. 89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma.
Baczyk M; Czepczyński R; Milecki P; Pisarek M; Oleksa R; Sowiński J
Nucl Med Commun; 2007 Apr; 28(4):245-50. PubMed ID: 17325585
[TBL] [Abstract][Full Text] [Related]
11. [Myelotoxicity after systemic radionuclide therapy of painful bone metastases with 153Samarium-EDTMP ].
Dolezal J; Vizd'a J; Cermáková E
Vnitr Lek; 2003 Mar; 49(3):189-93. PubMed ID: 12728593
[TBL] [Abstract][Full Text] [Related]
12. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain.
Liepe K; Runge R; Kotzerke J
J Cancer Res Clin Oncol; 2005 Jan; 131(1):60-6. PubMed ID: 15449184
[TBL] [Abstract][Full Text] [Related]
13. Prospective dosimetry with 99mTc-MDP in metabolic radiotherapy of bone metastases with 153Sm-EDTMP.
Bianchi L; Baroli A; Marzoli L; Verusio C; Chiesa C; Pozzi L
Eur J Nucl Med Mol Imaging; 2009 Jan; 36(1):122-9. PubMed ID: 18751975
[TBL] [Abstract][Full Text] [Related]
14. (153)Sm-EDTMP for pain relief of bone metastases from prostate and breast cancer and other malignancies.
Correa-González L; Arteaga de Murphy C; Pichardo-Romero P; Pedraza-López M; Moreno-García C; Correa-Hernández L
Arch Med Res; 2014 May; 45(4):301-8. PubMed ID: 24681187
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases.
Turner JH; Claringbold PG; Hetherington EL; Sorby P; Martindale AA
J Clin Oncol; 1989 Dec; 7(12):1926-31. PubMed ID: 2585026
[TBL] [Abstract][Full Text] [Related]
16. Prospective 153Sm-EDTMP therapy dosimetry by whole-body scintigraphy.
Cameron PJ; Klemp PF; Martindale AA; Turner JH
Nucl Med Commun; 1999 Jul; 20(7):609-15. PubMed ID: 10423762
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic, Dosimetry and Toxicity Study of ¹⁷⁷Lu-EDTMP in Patients: Phase 0/I study.
Bal C; Arora G; Kumar P; Damle N; Das T; Chakraborty S; Banerjee S; Venkatesh M; Zaknun JJ; Pillai MR
Curr Radiopharm; 2016; 9(1):71-84. PubMed ID: 25771371
[TBL] [Abstract][Full Text] [Related]
18. (177)Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study.
Agarwal KK; Singla S; Arora G; Bal C
Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):79-88. PubMed ID: 25070686
[TBL] [Abstract][Full Text] [Related]
19. Samarium-153-EDTMP biodistribution and dosimetry estimation.
Eary JF; Collins C; Stabin M; Vernon C; Petersdorf S; Baker M; Hartnett S; Ferency S; Addison SJ; Appelbaum F
J Nucl Med; 1993 Jul; 34(7):1031-6. PubMed ID: 7686217
[TBL] [Abstract][Full Text] [Related]
20. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China.
Tian JH; Zhang JM; Hou QT; Oyang QH; Wang JM; Luan ZS; Chuan L; He YJ
Eur J Nucl Med; 1999 Jan; 26(1):2-7. PubMed ID: 9933654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
